Hui Wang

Summary

Affiliation: Novartis Institutes for BioMedical Research

Publications

  1. pmc Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study
    Jun Guo
    Peking University Cancer Hospital and Institute, No 52, Fucheng Road, Beijing 100142, China
    BMC Cancer 13:136. 2013
  2. pmc Two-dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors
    Binghe Xu
    Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
    J Hematol Oncol 4:3. 2011

Detail Information

Publications2

  1. pmc Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study
    Jun Guo
    Peking University Cancer Hospital and Institute, No 52, Fucheng Road, Beijing 100142, China
    BMC Cancer 13:136. 2013
    ..This phase 1b study was designed to further evaluate the safety and efficacy of everolimus in VEGFr-TKI-refractory Chinese patients with mRCC...
  2. pmc Two-dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors
    Binghe Xu
    Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
    J Hematol Oncol 4:3. 2011
    ..This phase I, randomized, multicenter, open-label study investigated the pharmacokinetics, safety, and efficacy of the oral mammalian target of rapamycin inhibitor everolimus in Chinese patients with advanced solid tumors...